Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Learn more about:
Related Clinical Trial
Optimising Molecular Radionuclide Therapy Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer Function Integrity of Neck Anatomy in Thyroid Surgery An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Evaluation of a New CZT System Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain A Study Into the Effect of Seprafilm in Open Total Thyroidectomy Lenvatinib and Pembrolizumab in DTC Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Influence of Thyroid Hormones on the Woundhealing Process ctDNA in Patients With Thyroid Nodules Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine Trial of LBH589 in Metastatic Thyroid Cancer Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma Thyroid Cancer and Sunitinib Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients Lipid Metabolic Status in Thyroid Carcinoma

Brief Title

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Official Title

A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy

Brief Summary

      This phase II trial is studying how well aflibercept works in treating patients with
      recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine
      therapy. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor
      and by carrying tumor-killing substances directly to thyroid cancer cells.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To determine the radiographic response rate (by RECIST criteria) of IV VEGF Trap after
      four cycles (approximately 8 weeks) of therapy, as well as the 6-month
      progression-free-survival (PFS) rate (as part of a composite primary outcome measure), in
      patients with recurrent and/or metastatic differentiated thyroid carcinoma of follicular cell
      origin (D-TC-FCO; comprising papillary, follicular, Hurthle cell, and respective variants)
      not amenable to RAI or curative surgery.

      SECONDARY OBJECTIVES:

      I. To determine the safety and toxicity profile of IV VEGF Trap in patients with recurrent
      and/or metastatic TC-FCO. Please see the adverse event table for the specifics for this
      protocol.

      II. To determine the biologic effect of IV VEGF Trap on FDG avidity after four cycles
      (approximately 8 weeks) of therapy through pre- and post-treatment FDG-PET scans in patients
      with recurrent and/or metastatic D-TC-FCO.

      III. To determine if changes in thyroglobulin concentration after four cycles (approximately
      8 weeks) of IV VEGF-Trap therapy correlate with radiographic response after four cycles
      (approximately 8 weeks) and progression-free-survival at 6 months after start of therapy in
      patients with recurrent and/or metastatic D-TC-FCO.

      IV. To determine if pre-treatment serum VEGF concentration correlates with clinical outcomes
      after IV VEGF Trap therapy in patients with recurrent and/or metastatic D-TC-FCO.

      TERTIARY OBJECTIVES:

      I. To determine population pharmacokinetics of IV VEGF Trap for patients with thyroid cancer.

      II. To determine whether antibodies to VEGF Trap develop in patients with thyroid cancer.

      OUTLINE:

      Patients receive aflibercept intravenously (IV) over 1 hour on day 1.

      Treatment repeats every 14 days for up to 12 months in the absence of disease progression or
      unacceptable toxicity. Patients experiencing clear clinical benefit with aflibercept may
      continue treatment beyond 12 months, at the discretion of the study sponsor. Patients undergo
      fludeoxyglucose F 18 (FDG)-PET scans at baseline and after 8 weeks of study therapy to
      evaluate changes in FDG avidity on FDG-PET scan. Blood samples are obtained at baseline and
      periodically during study for laboratory correlative studies. Samples are examined for
      pretreatment serum VEGF concentration, thyroglobulin levels (when elevated), serum
      pharmacokinetics of aflibercept by ELISA, and anti-aflibercept antibodies.

      After completion of study therapy, patients are followed up for 2-4 months.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Progression-free Survival to Determine the 6-month Progression-free-survival (PFS) Rate

Secondary Outcome

 The Safety and Toxicity Profile of IV VEGF Trap in Patients With Recurrent and/or Metastatic TC-FCO

Condition

Recurrent Thyroid Gland Carcinoma

Intervention

Fludeoxyglucose F-18

Study Arms / Comparison Groups

 Treatment (ziv-aflibercept and fludeoxyglucose F 18)
Description:  Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients experiencing clear clinical benefit with aflibercept may continue treatment beyond 12 months, at the discretion of the study sponsor. Patients undergo FDG-PET scans at baseline and after 8 weeks of study therapy to evaluate changes in FDG avidity on FDG-PET scan. Blood samples are obtained at baseline and periodically during study for laboratory correlative studies. Samples are examined for pretreatment serum VEGF concentration, thyroglobulin levels (when elevated), serum pharmacokinetics of aflibercept by ELISA, and anti-aflibercept antibodies.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Radiation

Estimated Enrollment

41

Start Date

August 2008

Completion Date

November 2012

Primary Completion Date

October 2012

Eligibility Criteria

        Inclusion Criteria:

          -  Histopathologically confirmed differentiated thyroid carcinoma of follicular cell
             origin, including any of the following histologies and their respective variants:

               -  Papillary

               -  Follicular

               -  Hürthle cell

          -  Must have surgically inoperable and/or recurrent or metastatic disease

          -  At least one fludeoxyglucose F 18 (FDG)-PET-avid lesion, defined as any focus of
             increased FDG uptake > normal mediastinal activity with standard uptake variable (SUV)
             maximum levels ≥ 3, as documented by baseline PET scan

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
             conventional techniques or ≥ 10 mm by spiral CT scan

          -  Progressive disease, defined by ≥ 1 of the following occurring during or after prior
             treatment (e.g., radioactive isotope [RAI] treatment):

               -  Presence of new or progressive lesions on CT scan or MRI

               -  New lesions on bone scan or PET scan

               -  Rising thyroglobulin level documented by a minimum of 3 consecutive rises, with
                  an interval of > 1 week between each determination

          -  No known history of brain metastasis

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

          -  ANC ≥ 1,500/mcL

          -  Platelet count ≥ 75,000/mcL

          -  WBC ≥ 3,000/mcL

          -  Total bilirubin ≤ 1.5 times upper limit of normal(ULN)

          -  AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for liver metastases)

          -  Creatinine ≤ 1.5 times ULNOR creatinine clearance ≥ 60 mL/min

          -  INR ≤ 1.2 (≤ 1.5 times ULN if on prophylactic-dose anticoagulation)

          -  Urine protein: creatinine ratio < 1 OR 24-hour urine protein < 500 mg

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 6 months after
             completion of study therapy

          -  Documentation of systolic blood pressure ≤150 mm Hg and diastolic blood pressure ≤100
             mm Hg

          -  No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
             human antibodies

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to other agents used in the study

          -  No serious or non-healing wound, ulcer, or bone fracture

          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess in the
             past 28 days

          -  No significant traumatic injury within the past 28 days

          -  No clinically significant cardiovascular disease, defined as any of the following:

               -  Cerebrovascular accident within the past 6 months

               -  Myocardial infarction within the past 6 months

               -  Coronary artery bypass grafting or unstable angina within the past 6 months

               -  NYHA grade III-IV congestive heart failure

               -  Canadian Cardiovascular Class grade III or greater angina within the past 6
                  months

               -  Clinically significant peripheral vascular disease within the past 6 months

               -  Pulmonary embolism, deep-vein thrombosis, or other thromboembolic event within
                  the past 6 months

               -  Uncontrolled coronary artery disease, angina, congestive heart failure, or
                  ventricular arrhythmia requiring acute medical management

               -  Myocardial infarction, cerebrovascular accident, or transient ischemic attack
                  within the past 6 months

          -  No evidence of bleeding diathesis or coagulopathy within the past 12 months

          -  No uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection or psychiatric illness or social situation that would limit study compliance

          -  No known HIV positivity

          -  See Disease Characteristics

          -  Recovered from prior therapy

          -  No prior VEGF-targeted antibody therapy (e.g., bevacizumab or aflibercept)

          -  More than 4 weeks since prior systemic therapy or radiotherapy

          -  More than 7 days since prior core biopsy

          -  Up to 1 prior targeted biologic agent (e.g., small-molecule tyrosine kinase inhibitor
             or histone deacetylase inhibitor) allowed provided treatment was stopped ≥ 4 weeks
             prior to initiation of therapy on this study

          -  Up to 1 prior cytotoxic chemotherapy (e.g., doxorubicin hydrochloride) allowed
             provided treatment was stopped ≥ 4 weeks prior to initiation of therapy on this study

          -  Prior systemic chemotherapy administered as part of initial definitive treatment
             (e.g., as a radiation sensitizer or as initial adjuvant therapy) allowed provided
             treatment was stopped ≥ 3 months prior to initiation of therapy on this study and does
             not count in the determination of prior targeted or cytotoxic therapy

          -  At least 2 weeks since prior cyclooxygenase-2 (COX-2) inhibitors, cis-retinoic acid,
             or complementary medications if given with anti-cancer intent

               -  Medications given for a specific clinical indication (e.g., daily aspirin status
                  post myocardial infarction or COX-2 inhibitors at standard anti-inflammatory/pain
                  doses) may be continued based on the clinical judgment of the involved
                  investigator

          -  Prior RAI therapy allowed provided it was stopped > 3 months prior to initiation of
             therapy on this protocol and evidence of progression (as defined above) has been
             documented in the interim

               -  A diagnostic study using < 10 mCi of RAI is not considered RAI therapy

          -  Prior external-beam radiotherapy to index lesions allowed provided there has been
             documented progression by RECIST criteria and at least 4 weeks have elapsed

               -  At least 4 weeks since prior external-beam radiation therapy to non-index lesions

          -  At least 4 weeks since prior surgery

          -  Concurrent therapeutic-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 allowed
             provided that both of the following criteria are met:

               -  In-range INR appropriate to the treatment indication (e.g., between 2 and 3 for
                  atrial fibrillation) AND on a stable dose of oral anticoagulant or on a stable
                  dose of low molecular weight heparin

               -  No active bleeding or pathological condition that carries a high risk of bleeding
                  (e.g., tumor involving major vessels or known varices)

          -  Patients receiving concurrent antihypertensive agents must have documentation of the
             date of the last change in dosage

          -  No other concurrent investigational agents

          -  No major surgical procedure or open biopsy within the past 28 days

          -  No anticipation of need for major surgical procedures during the course of the study
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

David Pfister, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00729157

Organization ID

NCI-2009-00178

Secondary IDs

NCI-2009-00178

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)


Study Sponsor

David Pfister, Principal Investigator, Memorial Sloan Kettering Cancer Center


Verification Date

January 2017